Celltrion, Inc. Share Price Korea S.E.
Equities
068270
KR7068270008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- KRW | - |
24/04 | Market Share of Celltrion’s Remsima Rises to 74% in Europe | MT |
17/04 | Celltrion, Inc. announces an Equity Buyback for 436,047 shares. | CI |
Sales 2024 * | 3,472B 2.56B 214B | Sales 2025 * | 4,214B 3.11B 259B | Capitalization | 39,175B 28.91B 2,411B |
---|---|---|---|---|---|
Net income 2024 * | 529B 390M 32.55B | Net income 2025 * | 1,150B 849M 70.76B | EV / Sales 2024 * | 11.4 x |
Net Debt 2024 * | 526B 388M 32.37B | Net cash position 2025 * | 128B 94.19M 7.85B | EV / Sales 2025 * | 9.27 x |
P/E ratio 2024 * |
73.2
x | P/E ratio 2025 * |
33.9
x | Employees | - |
Yield 2024 * |
0.22% | Yield 2025 * |
0.23% | Free-Float | 63.31% |
Managers | Title | Age | Since |
---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 24/07/24 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Soon-Woo Lee
BRD | Director/Board Member | 73 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jong-Seok Lee
BRD | Director/Board Member | 72 | 08/14/08 |
1st Jan change | Capi. | |
---|---|---|
+25.69% | 48.09B | |
+46.90% | 40.62B | |
-3.46% | 40.43B | |
+9.17% | 24.89B | |
-20.42% | 19.01B | |
+28.07% | 12.09B | |
+0.17% | 11.88B | |
-1.24% | 11.8B | |
+19.33% | 11.45B |
- Stock Market
- Equities
- A068270 Stock
- 068270 Stock